View Item 

Show simple item record

Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center
dc.contributor.authorFung, Scott K.en_US
dc.contributor.authorWong, Florence S. H.en_US
dc.contributor.authorWong, David K. H.en_US
dc.contributor.authorHussain, Munira T.en_US
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.date.accessioned2010-06-01T18:34:24Z
dc.date.available2010-06-01T18:34:24Z
dc.date.issued2006-09en_US
dc.identifier.citationFung, Scott K . ; Wong, Florence S . H . ; Wong, David K . H . ; Hussain, Munira T . ; Lok, Anna S . F . (2006). "Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center." Liver International 26(7): 796-804. <http://hdl.handle.net/2027.42/71778>en_US
dc.identifier.issn1478-3223en_US
dc.identifier.issn1478-3231en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71778
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16911461&dopt=citationen_US
dc.description.abstractThe epidemiology of hepatitis B virus (HBV) infection in North America may be changing as a result of immigration from endemic countries. The purpose of this study was to determine the prevalence of HBV genotypes, precore (PC) and core promoter (CP) variants, and the proportion of patients meeting treatment criteria for HBV. Methods : A cross-sectional study of consecutive HBV patients attending a Canadian tertiary liver center was conducted. HBV DNA was quantified by polymerase chain reaction assay. HBV genotypes and variants were determined using a line probe assay. Results : Two hundred and seventy-two patients were enrolled; 200 were not receiving treatment at enrollment, of whom 116 were men and 84 women with a mean age 42±14 years. Among this group, 177 (88%) patients were Asian and 19 (10%) were Caucasian and 69 (35%) patients were hepatitis B e antigen (HBeAg) positive. Genotypes B and C were found in 42% and 50% untreated patients, respectively; while CP and PC were detected in 52% and 43% patients, respectively. Approximately 20% patients not receiving treatment (29% HBeAg positive, 14% HBeAg negative) met AASLD guidelines for antiviral therapy. If lower cutoff values for alanine aminotransferase and HBV DNA levels were used, 49% patients would qualify for treatment. Conclusions : The vast majority of patients at a Canadian tertiary referral center were Asian. Virological and clinical characteristics of these patients reflect their country of origin. Our findings highlight the need to monitor the changing patterns of HBV infection in countries with large immigrant populations.en_US
dc.format.extent166403 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2006 Blackwell Munksgaarden_US
dc.subject.otherAntiviral Therapyen_US
dc.subject.otherCore Promoter Varianten_US
dc.subject.otherHBV DNAen_US
dc.subject.otherHBV Genotypesen_US
dc.subject.otherHepatitis B Virusen_US
dc.subject.otherPrecore Varianten_US
dc.titleHepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian centeren_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Toronto, Toronto, ON, Canada ,en_US
dc.identifier.pmid16911461en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71778/1/j.1478-3231.2006.01297.x.pdf
dc.identifier.doi10.1111/j.1478-3231.2006.01297.xen_US
dc.identifier.sourceLiver Internationalen_US
dc.identifier.citedreferenceMcMahon B, Alberts S R, Wainwright R B, Bulkow L, Lanier A P. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaskan native carriers. Arch Internal Med 1990; 150: 1051 – 4.en_US
dc.identifier.citedreferenceMcMahon B, Holck P, Bulkow L, Snowball M M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Internal Med 2001; 135: 759 – 68.en_US
dc.identifier.citedreferenceMinuk G, Uhanova J. Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol 2003; 17: 707 – 12.en_US
dc.identifier.citedreferenceMiller J, Finelli L, Bell B P. Incidence of acute hepatitis B – United States, 1990–2002. J Am Med Assoc 2004; 291: 416 – 47.en_US
dc.identifier.citedreferenceLindh M, Andersson A, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus – large scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285 – 93.en_US
dc.identifier.citedreferenceMagnius L O, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38: 24 – 34.en_US
dc.identifier.citedreferenceSugauchi F, Orito E, Ichida T, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002; 76: 5985 – 92.en_US
dc.identifier.citedreferenceSugauchi F, Kumada H, Sakugawa H, et al. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin Infect Dis 2004; 38: 1222 – 8.en_US
dc.identifier.citedreferenceSugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124: 925 – 32.en_US
dc.identifier.citedreferenceJanssen H L, Senturk H, Zeuzem S, et al. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive chronic hepatitis B: a randomized controlled trial in 307 patients (abstract). Hepatology 2003; 38 :( Suppl ): 246A.en_US
dc.identifier.citedreferenceChu C, Hussain M, Lok A. Hepatitis B virus genotype B is associated with earlier spontaneous seroconversion than hepatitis B virus genotype C. Gastroenterology 2003; 122: 1756 – 62.en_US
dc.identifier.citedreferenceChan H L Y, Wong M L, Hui A Y, Hung L C T, Chan F K L, Sung J J Y. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol 2003; 41: 1277 – 9.en_US
dc.identifier.citedreferenceYuen M F, Fung S K, Tanaka Y, et al. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004; 42: 5036 – 40.en_US
dc.identifier.citedreferenceJanssen H L, van Zonneveld M, Senturk H, et al. Pegylated interferaon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123 – 9.en_US
dc.identifier.citedreferenceCarman W F, Jacyna M R, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588 – 91.en_US
dc.identifier.citedreferenceNaoumov N V, Schneider R, Grotzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538 – 43.en_US
dc.identifier.citedreferenceChu C M, Chiu C T, Sheen I S, Liaw Y F, Yeh C T. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol 1996; 34: 1815 – 8.en_US
dc.identifier.citedreferenceLaras A, Koskinas J, Avgidis K, Hadziyannis S J. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5: 241 – 8.en_US
dc.identifier.citedreferenceBrunetto M R, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198 – 202.en_US
dc.identifier.citedreferenceGrandjacques C, Paradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33: 430 – 9.en_US
dc.identifier.citedreferenceChu C J, Keefe E, Han S H, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125: 444 – 51.en_US
dc.identifier.citedreferenceChu C J, Keeffe E, Han S H, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 619 – 28.en_US
dc.identifier.citedreference23.  Anonymous. Hepatitis B vaccination coverage among Asian and Pacific Islander children – United States, 1998. Morbid Mortal Weekly Rep 2000; 49: 616 – 9.en_US
dc.identifier.citedreferenceChao S, Le P V, Prapong W, Su J, So S. High prevalence of chronic hepatitis B (HBV) infection in Chinese Americans living in California (abstract). Hepatology 2004; 40 ( Suppl. 1 ): 717A.en_US
dc.identifier.citedreferenceLok A, McMahon B. Chronic Hepatitis B. Hepatology 2001; 34: 1225 – 41.en_US
dc.identifier.citedreferenceLok A S F, McMahon B J. Chronic Hepatitis B: update of recommendations. Hepatology 2004; 39: 857 – 61.en_US
dc.identifier.citedreferenceChan H L Y, Hussain M, Lok A S. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29: 976 – 84.en_US
dc.identifier.citedreferenceLok A S F, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145 – 53.en_US
dc.identifier.citedreferenceLok A S F, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729 – 34.en_US
dc.identifier.citedreference30.  Statistics Canada. Census 2001, http://www.statcan.ca. 2001.en_US
dc.identifier.citedreference31.  EASL Jury. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003; 39: S3 – 25.en_US
dc.identifier.citedreferenceLiaw Y F, Leung N W, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472 – 89.en_US
dc.identifier.citedreferenceSherman M, Bain V, Villeneuve J P, et al. Management of viral hepatitis: a Canadian Consensus Conference 2003/2004. Can J Gastroenterol 2004; 18: 715 – 28.en_US
dc.identifier.citedreferenceKeeffe E, Dieterich D T, Han S H B, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 86 – 107.en_US
dc.identifier.citedreferenceChan H, Leung N, Hussain M, Wong M, Lok A. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763 – 8.en_US
dc.identifier.citedreferenceKim W R, Benson J T, Therneau T M, Torgerson H A, Yawn B P, Melton L J III. Changing epidemiology of hepatitis B in a US community. Hepatology 2004; 39: 811 – 6.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1478-3231.2006.01297.x.pdf
Size:
162.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.